Aromatic L-amino acid decarboxylase inhibitor

From Infogalactic: the planetary knowledge core
Jump to: navigation, search

An aromatic L-amino acid decarboxylase inhibitor (synonyms: DOPA decarboxylase inhibitor, DDCI and AAADI) is a drug which inhibits the synthesis of dopamine by the enzyme aromatic L-amino acid decarboxylase (AAAD, or DOPA decarboxylase, DDC).

Indications

Peripheral DDCIs incapable of crossing the protective blood-brain-barrier (BBB) are used in augmentation of L-DOPA (Levodopa) in the treatment of Parkinson's disease (PD) to block the peripheral conversion of L-DOPA into dopamine for the purpose of reducing adverse side effects.[1] Combined l-dopa and DDCI therapy does not inherently decrease peripheral cardiovascular side effects of l-dopa administration; however, combined therapy potentiates the central effects of l-dopa by decreasing the dose-dependency 4-5 fold, therein allowing for effective Parkinson's Disease treatment without cardiovascular risk associated with high peripheral dopamine.[2][3]

List of DDCIs

  • Benserazide (Madopar, Prolopa, Modopar, Madopark, Neodopasol, EC-Doparyl, etc.)
  • Carbidopa (Lodosyn, Sinemet, Parcopa, Atamet, Stalevo, etc.)
  • Methyldopa (Aldomet, Aldoril, Dopamet, Dopegyt, etc.)
  • DFMD

References

  1. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ Cotzias, G. C., Papavasiliou, P. S., and Gellene, R., New England Journalof Medicine, 1969, 280, 337.
  3. ↑ Yahr, M. D., in Advances in Neurology, ed. M. D. Yahr, p. vi, vol. 2. New York, Raven Press, 1973.


<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.
Retrieved from "https://infogalactic.com/w/index.php?title=Aromatic_L-amino_acid_decarboxylase_inhibitor&oldid=5407010"